Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

M5353

Sigma-Aldrich

Mitomycin C

liquid, non-animal origin, suitable for cell culture, BioReagent

Sinonimo/i:

Ametycine, MMC, MitoExtra, Mitocin C, Mitomycin, Mitonco, Mitoplus, Mitozytrex, Mutamycin

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali


About This Item

Codice UNSPSC:
12352207
NACRES:
NA.76

product name

Mitomycin C ready made solution, 10 mg/mL in DMSO, ≥98% (HPLC), Cell culture tested

Livello qualitativo

Saggio

≥98% (HPLC)

Forma fisica

liquid

Condizioni di stoccaggio

protect from light

Concentrazione

10 mg/mL in DMSO

Temperatura di conservazione

−20°C

Descrizione generale

Mitomycin C (MMC) produced by Streptomyces caespitosus is an anticancer antibiotic agent which inhibits proliferation of various cell types in vitro. MMC is DNA alkylating agent, that causes cross linking of complementary DNA strands resulting in: mutagenesis, inhibition of DNA synthesis, initiation of DNA repair events, and activation of apoptosis. Furthermore, MMC has an effect on ribosomal RNA leading to protein synthesis inhibition.
MMC is capable of inhibiting cell proliferation of human or murine embryonic fibroblast cells at concentration range of 0.2-20μg/mL. These treated cells are subsequently used as an adherent feeder layer in long-term culture assays mainly for growth of pluripotent stem cells. Feeder layer cells support the target cells by releasing growth factors to the cell culture and detoxification of the medium. Moreover, feeder layer cells play a role in ECM proteins synthesis that controls cell culture growth. In addition, feeder layer cells are used as a substrate for attachment of the target cells.
MMC also was used for BLC (basal-like cancer) cell line.
MMC as antibiotic agent showed a potent activity against MDR gram-negative bacteria like P. aeruginosa (2 μg/mL), E.Coli (0.5μg/mL) and A. baumannii (16μg/mL). MMC also has a strong activity against gram positive bacteria (0.2μg/mL).

Technical information
1.Mitomycin C ready made solution provides a safer alternative to the powder form by preventing hazardous particles exposure.
2.Please avoid repeated freeze thaw cycles of this product.
3.Mitomycin C solutions are light sensitive and should kept in the dark.
4.It is recommended to keep Mitomycin C solutions at pH 6-7.
5.The recommended concentration of Mitomycin C in cell culture assays is 0.2-20μg/mL. (Ref.8,9,12,13) Therefore, it is recommended to dilute the ready made solution 1:500-50,000.

Avvertenza

Light sensitive

Stato fisico

Liquid - In DMSO

Codice della classe di stoccaggio

10 - Combustible liquids

Classe di pericolosità dell'acqua (WGK)

WGK 2

Punto d’infiammabilità (°F)

188.6 °F - closed cup

Punto d’infiammabilità (°C)

87 °C - closed cup


Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

L Ponchio et al.
Cytotherapy, 2(4), 281-286 (2002-06-04)
Mitomycin C (MMC), an antitumoral antibiotic, has been described inhibiting the proliferation of different cell types in vitro. Since irradiation is commonly used to stop the cell growth of adherent cells in several experimental models, we aimed to define the
Ronald Domalaon et al.
Frontiers in microbiology, 10, 1556-1556 (2019-07-30)
The lack of therapeutic options to treat infections caused by multidrug-resistant (MDR) pathogens, especially Gram-negative bacteria, is apparent. Therefore, it is imperative to develop new strategies to address the problem of antimicrobial resistance. Repurposing non-antibiotic commercial drugs for antimicrobial therapy
Sarah J Hill et al.
Molecular and cellular biology, 34(20), 3828-3842 (2014-08-06)
Sporadic basal-like cancers (BLCs) are a common subtype of breast cancer that share multiple biological properties with BRCA1-mutated breast tumors. Despite being BRCA1(+/+), sporadic BLCs are widely viewed as phenocopies of BRCA1-mutated breast cancers, because they are hypothesized to manifest

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.